• Trading volume increased rapidly during the first four days of trading
• Company has excellent prospects on vacation rental market, which totaled nearly $68 billion in revenue in 2019
• InsuraGuest’s Hospitality Liability Policy covers a wide range of issues, being designed to serve as the first line of defense for guests and properties alike

InsuraGuest Technologies Inc. (TSX.V: ISGI) commenced trading common shares on the TSX Venture Exchange at the opening bell on Friday, February 28, 2020. The company opened with a trading volume of 2,000 shares at $0.4 per share. The price dipped slightly but began rising again as the trading volume increased significantly to more than 200,000 shares over the following days.

Trading volume and share price evolution during the first four days of trading are detailed below:

InsuraGuest Technologies has developed a proprietary insurtech platform, called InsuraGuest, it is designed to deliver specialized insurance products to the hotel and vacation rental market. The specialized guest protection policy, called the Hospitality Liability Policy, serves as the first line of defense for both the property and the guest.

Hotels and vacation rental properties purchase an InsuraGuest Hospitality Liability Policy. This policy is then automatically placed on the guest folio as a mandatory charge at the time of check in. The property pays for the policy on a nightly per-guest basis, which they pass along to the guest, and this is where the company generates revenue.

The platform was created to fill the gap that traditional traveler’s insurance misses, as this type of insurance does not cover a number of things that can happen inside hotels or other travel properties, putting at risk both the traveler and the property owner. People often mistakenly assume that accidents happening at such a property are automatically covered by the property owner’s insurance, but that is not always the case.

Because InsuraGuest extends beyond hotels to the vacation rental industry, the growth potential in companies like Airbnb and VRBO is encouraging for InsuraGuest’s investors. With over $57 billion in rental revenue in 2019 and a growth rate of 6.9% (http://ibn.fm/CFVRH), the vacation rental industry continues to expand as more and more people each year take advantage of the variety of benefits vacations rentals offer.

The company’s insurtech platform can integrate with around 71 different property management systems, giving it access to millions of rooms worldwide and to significant growth opportunities in larger markets. Europe’s hospitality stay market is more than double the market size in the United States, indicating room for significant potential in serving hotel and vacation rental guests with InsuraGuest’s insurance platform.

As the company’s Hospitality Liability Policy covers a wide range of issues, including in-room damage and lost and stolen goods, and provides coverage for accidental, medical, death or dismemberment, InsuraGuest can be a valuable partner to hospital and vacation rental entities, helping them minimize damaging publicity about adverse events by offering a comprehensive insurance solution.

For more information, visit the company’s website at www.InsuraGuest.com

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Brands that partner with Vocal see unmatched results, impressive metrics compared to branded content industry averages
• Exclusive Vocal communities offer brands access to authentic partners and ability to target their ideal audience
• Jerrick focuses on creating technology platforms for the creative community and is the parent company of Vocal

Building a brand and establishing a presence in today’s digital-first consumer world is next to impossible without help and support from a tech-savvy strategic partner. Luxury skincare brand FOREO recognized this and chose to partner with Jerrick Media Holdings Inc. (OTC: JMDA), the parent company of the Vocal platform and the Vocal for Brands content studio (http://ibn.fm/ZIt9C).

The result? During the campaign period, FOREO’s website received an 8.4% click through from Vocal’s branded stories – nearly 33 times the industry standard CTR for branded content (http://ibn.fm/XlBmf). The branded content campaign’s initial goal included a Vocal read reach of 25k reads. The campaign exceeded this benchmark by over 10k, resulting in 36,500 engaged readers in the short promotional period (http://ibn.fm/bMYp9).

FOREO, which has been described as “the Apple of the skincare industry,” has 20 million customers worldwide and has grown from two employees to more than 3,000 in the past five years. Yet FOREO officials still recognized the need for a tech partner. Together, Vocal and FOREO created an authentic campaign designed to connect beauty-focused readers on Vocal’s network with FOREO’s brand.

As part of the campaign, Vocal paired FOREO with an existing creator on its beauty community, Blush (http://ibn.fm/AGkeu), to create a series of stories focused on FOREO’s products. The stories included detailed reviews of products and were designed to be informative for FOREO’s current audience while inspiring interest and awareness for readers from the Blush audience.

“By partnering with Vocal for its Winter 2018 campaign, FOREO drove awareness and conversions for its product line to new and existing audiences,” the case study for the campaign reports. “With 36,500 reads, an average CTR of 8.4%, and an interactive female audience representing 97% of total engagement, the branded content campaign successfully resonated with Blush creators and readers.”

FOREO’s experience is not unique. Over and over again, companies report similar results when they partner with Jerrick. The company’s expertise in the development of digital communities and the targeted marketing of branded digital content is unmatched.

Another example is INTIMINA (http://ibn.fm/vKp2j), which offers a range of products dedicated to all aspects of women’s intimate health. The company found ad restrictions around their products’ intimate nature which made traditional marketing and advertising difficult – so they turned to Vocal. Over the period of a year, Vocal and INTIMINA created a series of unique branded stories designed to promote specific products within Vocal’s Viva community (http://ibn.fm/MEJzJ); Viva explores the lives of women from the workplace to home, family, adventure, ambition and beyond (http://ibn.fm/UtTk2).

As detailed in one of the Vocal platform’s case studies (http://ibn.fm/9Cnuo), “Vocal for Brands helped INTIMINA drive awareness and reach new audiences, effectively overcoming the obstacle of restrictions on Facebook and other platforms surrounding themes of women’s health,” the campaign case study reports. “The ongoing campaign has generated over 125,000 reads in total so far and has seen an average CTR of 3% on product-focused campaign stories – a rate that’s 12x the industry standard for branded content. With an average time on page of two and a half minutes, the story series has resulted in over 5,300 hours of engaged readership.”

Jerrick Media Holdings is focused on the development of digital communities, targeted marketing of branded digital content and e-commerce opportunities. To accomplish these objectives, Jerrick envisions, designs and builds modern technology companies that redefine how people interact with technology. As the parent company of Vocal, Jerrick has built and shipped products that have influenced millions of people worldwide.

Those interested in weekly news from Jerrick can sign up at http://ibn.fm/CYErP

For more information, visit the company’s website at https://Jerrick.media

NOTE TO INVESTORS: The latest news and updates relating to JMDA are available in the company’s newsroom at http://ibn.fm/JMDA

• Trxade Group has captured nearly half of the independent pharmacy market with its web-based purchasing platform
• “E-Bay/Kayak-like” Supplier-to-Pharmacy trading platform improves transaction processing between independent pharmacists and drug distributors
• Predictive data analytics features, price visibility and profit optimization within the platform are critical as the general population ages

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform for transactions between independent pharmacists and drug distributors; a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

The Florida-based Company’s Supplier-to-Pharmacy (“S2P”) trading platform helps independent pharmacies nationwide to identify the best available supplier prices for prescription drugs. With over 11,900 registered pharmacies already on the company’s network, and adding approximately 100 new pharmacies per month, Trxade’s aim is to ultimately reach most of the 24,000 independent pharmacies, with a combined annual purchasing power of over $92 billion.

Trxade targets these independent pharmacies and has demonstrated a significant first-mover advantage over competitors operating similar e-commerce platforms. The company credits effective analytics deployment for the results attained. Trxade leverages a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

The platform has experienced unparalleled success due to the fact that the company’s business model is designed to overcome general obstacles faced by the typical independent pharmacy. Trxade has found that these pharmacies average annual sales of approximately $3.5 million and the average age of an independent pharmacy owner is greater than 60. Further, independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The Trxade S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving them money by taking advantage of best purchase pricing.

As the general population ages, drug costs are paced to increase faster than overall health care costs and well above inflation. Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

The company’s operating strategy is also contributing to its bright outlook for 2020. Trxade’s web-based platform makes it safe, secure and easy to review drugs offered by various suppliers and select the most favorable deals. This increases supplier competition and effectively lowers prices for the pharmacies, enabling them to enjoy larger profit margins.

Information sharing through direct marketing, email marketing, and trade conference attendance, has resulted in the company’s current trend of adding more than 100 pharmacies per month to its user base.

User satisfaction is yet another factor driving success. Pharmacies now have access to quality pharmaceuticals at significant discounts and a large network of suppliers for sales and purchasing opportunities. The analytical and price comparison tools allow for educated buying and selling decisions, easier price comparisons of multiple suppliers with only one search and simplified ordering to suppliers of choice. Customer service is first-class, as Trxade offers close guidance and support to pharmacies for their five initial purchases.

The company believes investors, consumers and industry stakeholders are poised to benefit in the near term from its recent deployment of superior data analytics as well as a platform specifically tailored to current industry needs.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• CEO announces that company will sponsor infomercials touting benefits of CBD oil sold through CBD Biotech Co. subsidiary
• CBD-oil awareness campaign consists of China AM radio infomercial, WeChat group infomercial and New York radio infomercial
• CIIX planning to expand CBD product offerings in China

ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang announced during a MoneyTV interview that CIIX is launching a media campaign to raise awareness of the benefits of CBD oil (http://ibn.fm/PqQCy). The multimedia campaign consists of three infomercials: one aired on AM radio in China, one posted on WeChat and one aired on New York radio.

“A lot of people do not understand the benefits of CBD oil,” Wang noted during the broadcast interview. Sharing the benefits of CBD oil is a priority for the company because its China subsidiary, CBD Biotech Co., is expanding its CBD product offerings.

During his interview with MoneyTV host Donald Baillargeon, Wang said the purpose of the media campaign is to raise awareness – and ultimately sales – of CBD oil products offered by CBD Biotech.

“We will have an infomercial in an AM radio show in China for one month to start to create an awareness campaign to explain the benefits of CBD oil and the differences between full-spectrum CBD and CBD isolate,” Wang said. “We believe that CBD oil is very helpful to your health. We see CBD oil as a huge, huge market over the next three-six months.”

The educational infomercial by CIIX shared on a WeChat group site puts the company’s CBD-oil media-awareness campaign at the heart of Chinese social media. WeChat is a multipurpose messaging, social-media and payment app popular with consumers and used for everything from games, video calls, food ordering and news content. WeChat is China’s largest messaging app with a base of more than one billion people. The New York radio infomercial also raises the company’s profile in the United States and with its American audience of Chinese-speaking investors.

In addition to the campaign, CIIX’s website — ChineseInvestors.com — explains the health benefits of CBD oil and details where consumers can buy CBD oil through the company’s online store. Online consumers can also purchase hemp-derived CBD products such as soft gels, capsules and concentrates on the site. The site also educates consumers about CBD, the CBD market and the differences between full-spectrum CBD and CBD isolate.

During the interview, Wang also noted that the company plans on using social-media multiplatform techniques to market CBD products as it moves to boost online sales in China through CBD Biotech Co.

In earlier interviews, Wang noted that, through e-commerce and social-media platform promotion, he sees CBD Biotech reaching profit starting in the fourth quarter of 2020 fiscal year and throughout 2021 fiscal year.

Besides offering its audience of investors real-time market commentary, analysis and educational-related services, CIIX also provides consulting services to smaller private companies looking to go public, in addition to advertising, social media, and public relations consulting services. Based in San Gabriel, California, the company was created in 1999 and went public in 2011.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• Trends in environmental consciousness continue to shift global demand away from carbon-based cars toward electric vehicles
• Bolt Metals Corp. rebrands marketing strategy as part of plan to become the leading international player in the electric vehicle battery metal sector
• The company’s Cyclops drilling project is aligned perfectly to fit the supply chain criteria for the electric vehicle sector in Asia

A global shift away from carbon-based cars and trucks is pumping billions of dollars into battery-powered electric vehicle (EV) research and related development projects. Bolt Metals Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE), an exploration company focused on the acquisition and development of production grade cobalt and nickel deposits, is benefitting from the shift as demand for the materials that power EV research surges.

Nickel and cobalt are critical components of lithium-ion batteries used to power EV research. Both materials are currently experiencing a global supply deficit. Over $20 billion has been committed to nickel projects focused on the EV space in Indonesia alone.

Bolt Metals Corp. is redirecting its marketing strategy as it evolves to become a specific player in the expanding EV supply chain in both China and Indonesia, according to CEO Ranjeet Sundher in an interview with NetworkNewsAudio (http://ibn.fm/0VDTS). Sundher is a 25-year veteran of the mining and investor sectors in southeast Asia. Part of that new marketing strategy changed the company’s name from Pacific Rim Cobalt Corp. to Bolt Metals Corp. on February 26, 2020.

Bolt Metals Corp. employs a vertically integrated “minerals-to-market” strategy to leverage its production-grade battery metals projects to their fullest, Sundher said. The company’s flagship project, Cyclops (http://ibn.fm/jdjhA), is uniquely positioned within Indonesia, the world’s largest producer of nickel, and in proximity to China and features near surface, strong nickel-cobalt mineralization. The property is situated in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. Nestled on the north coast of Papua, Indonesia, Cyclops establishes the company well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

From drilling and permitting to processing ore and discussions with offtake partners, the results are promising. Sundher cited the project’s 99% recovery on nickel and 96% recovery on cobalt as two major factors that made 2019 such a pivotal year for the company. Those results provide solid evidence that the Cyclops project is aligned perfectly to fit the supply chain criteria for the EV sector in Asia, as the company’s end goal is to become a key contributor to Asia-Pacific’s rapidly expanding EV and battery supply chain.

Backed by a successful 2019 exploration and development season, the company is pursuing ambitious milestones for 2020, Sundher adds. Bolt Metals Corp. is working to show the market that it brings local know-how and exceptional project generation. “Quite early in our business plan, China’s largest battery manufacturer wanted to do a preliminary offtake with us, which demonstrated that we were in the right country with the right project. In 2020, we hope to take that relationship and several others to the next level,” Sundher explained.

The remainder of 2020 will see continued and consistent development in the company’s strategy as Bolt Metals Corp. continues to set ambitious milestones toward the goal of becoming the leading international player in the EV battery metal sector and creating significant long-term shareholder value. With rich mineral deposits and two substantial markets, Bolt Metals is anticipating a bright future.

For more information, visit the company’s website at www.BoltMetals.com

NOTE TO INVESTORS: The latest news and updates relating to PCRCF are available in the company’s newsroom at http://ibn.fm/PCRCF

• POAI’s planned acquisition of Quantitative Medicine (QM) will revolutionize the way precision therapies are developed
• QM’s CoRE platform predicts main effects of drugs on target molecules that mediate disease
• Synergies created by acquisition support POAI’s efforts to accelerate the commercialization of its AI-driven predictive model services

Predictive Oncology Inc. (NASDAQ: POAI) has announced the latest development in its mission to become the leader in the cancer precision-medicine field. In line with its focus on applying artificial intelligence (AI) to personalized medicine and drug discovery, POAI has signed a signed a Letter of Intent to acquire Quantitative Medicine (QM), a leading biomedical analytics and computational biology company (http://ibn.fm/8X3zm).

Founded by Drs. Robert Murphy and Joshua Kangas, both of Carnegie Mellon University, QM has developed a novel, computational drug-discovery platform called CoRE. This innovative platform predicts the main effects of drugs on target molecules that mediate disease, thereby dramatically reducing the time, cost and financial risk of discovering new therapeutic drugs. POAI’s planned acquisition of QM, which is subject to the negotiation of a definitive agreement and other terms and conditions, is expected to be complete by March 2020.

“By coupling QM’s CoRE predictive modeling platform with our tumor profiling expertise and data we believe we can revolutionize the way precision therapies are developed,” Dr. Carl Schwartz, president and CEO of Predictive Oncology, stated in a news release. Schwartz explained that the synergies created by the planned acquisition should be a major support in POAI’s efforts to accelerate the commercialization of its AI-driven technology and services.

Through its subsidiary Helomics, Predictive Oncology is building AI-driven predictive models of tumor drug response and outcomes from its data base of drug-response and genomics profiles gathered from more than 150,000 cancer cases. POAI plans to integrate its proprietary data and AI-driven predictive models with CoRE to rapidly build robust predictive models of how specific types of tumors will react to cancer drug therapies.

“Our goal is to provide researchers in pharma, biopharma and diagnostic companies with actionable insights that will not only drive the development of new precision therapies, companion diagnostics, and biomarkers, but will also help them design better targeted trials,” added Schwartz. “Working together, we have the potential to dramatically improve patient outcomes.”

CoRE was developed at what was originally the Ray and Stephanie Lane Center for Computational Biology; the center eventually became the Computational Biology Department at Carnegie Mellon University. CoRE has been tested by several pharma companies with considerable success. In addition to predicting the main effects of drugs on target molecules that mediate disease, CoRE is designed to predict the effects of drugs on other molecules or pathways in the body that could mediate adverse effects, as well as the interaction of these with underlying genetic variations.

Moreover, CoRE identifies similarities in relationships of drug candidates screened against a diverse matrix of pathogenic, cellular, molecular and/or systems biology targets. Drawing on CoRE’s unmatched ability to add new data from existing research or additional wet-lab experiments, POAI is confident that its predictive models will be improved—and with improved predictions comes accelerated drug discovery and development.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (PDx) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug repose to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Precision medicine, AI among top healthcare investment trends for 2020
• Predictive Oncology is data, AI-driven precision medicine company with an exclusive database of patient samples
• Market estimates for precision medicine expected to reach $84.6 billion by 2024

Precision medicine and artificial intelligence rank high on the list of top investment-focused healthcare trends, according to a recent Emagine article (http://ibn.fm/jALh4). Both are key areas of focus for Predictive Oncology Inc. (NASDAQ: POAI), a leading data and artificial-intelligence-driven precision medicine company. In an arena where data is king and artificial intelligence is increasingly gravitating to the spotlight, POAI is uniquely positioned with its historic database of patient samples and its cutting-edge AI-powered platform.

“We’ll see more progress in the next 10 years than we’ve seen in the past 50,” stated industry analyst Bill Gadless, who compiled the list of industry trends after attending the 38th annual J.P. Morgan Healthcare Conference. Gadless noted that the hot trends focus on “continuing to save, extend and improve lives.”

The annual conference, the largest and most informative healthcare investment symposium in the industry, brings together industry leaders, innovative technology creators, emerging fast-growth companies and other members of the investment community. Precision medicine received significant interest with its focus on matching up patients with precisely targeted treatments tailored to their unique genetic makeup. At the same time, AI was highlighted as an emerging and increasingly significant tool for use in clinical trials, practice management and digital-health diagnostics.

Emerging as one to watch in the industry, Predictive Oncology is bringing its cutting-edge technology to help pharmaceutical, diagnostic and biotech companies develop new therapies. Through its subsidiary Helomics, a leader in AI and functional precision medicine, POAI harnesses rich patient information gleaned from its PDx tumor profiling platform with the potential to revolutionize cancer research as it is seen today. Through the development of AI-driven predictive models that indicate how tumors respond to drugs, POAI will support clinicians in making decisions to individualize patient treatment. Additionally, these AI-driven models, together with the PDx tumor profiling platform can accelerate research into new targeted therapies.

Drug development for cancer treatment is a costly and time-intensive endeavor – the average drug takes upwards of 10 years and $3 billion to produce – and as technology plays an ever-increasing role in driving medicine, researchers and clinicians are discovering the significant potential of patient-derived PDx models in understanding the activity of potential new drugs on tumors. These models harness cancer cells from patient tumors to create a truly patient-centric future of precision medicine.

As a striking example of this intersection of research and technology, POAI’s Helomics clinical PDx platform compares the drug response and genomic profile of a patient’s own tumor grown in the lab with its database of over 150,000 existing tumor profiles to help recommend the best treatment for that patient. As additional patient samples are tested, they continue to enhance the database improving the recommendations. Leveraging the rich data in this database with AI to create AI-driven predictive models provides a valuable tool for pharmaceutical companies and researchers, offering a model that embodies actual drug response of cancer patients’ individual tumors and their outcomes (i.e. survival). This ability to build AI-driven predictive models of cancer puts the company in a powerful position to offer actionable insights to pharmaceutical companies much more quickly than its competitors.

According to Mordor Intelligence Inc., oncology is expected to have the largest share of the precision medicine market in excess of 30% over other segments, along with a CAGR of 10.3% from 2018 to 2024 (http://ibn.fm/1Uv7p). Eyeing the projected overall market estimate of $84.6 billion by 2024, POAI is positioning itself to capture a considerable portion of this growth potential with its unique proprietary technology.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Champignon’s Vitality SuperTea offerings revolutionizing conventional organic tea concept
• Each of Champignon’s tea options carefully formulated to provide unique health, performance benefits
• Global market for products infused with nutritional, bioactive mushroom ingredients projected to reach $34 billion by 2024

The future of health may reside in mushrooms. As buzzwords like ‘organic’, ‘whole’ and ‘fresh’ abound, it’s clear that society has become increasingly passionate about seeking high-quality, nutrient-rich foods. Recently, the humble mushroom has found itself in the spotlight as a surprisingly rich source of vitamins and minerals and a filling substitute for meat. Industry leaders like Four Sigmatic – which has been featured by The New York Times, Forbes, and Business Insider, among others – are working to educate the public on mushrooms’ superfood qualities.

Similarly, fresh on the publicly traded scene is small-but-mighty Champignon Brands Inc. (CSE: SHRM), a research-driven company specializing in mushroom health supplements that promote holistic health and wellness. SHRM is building a reputation as a leader in the burgeoning craft mushroom vertical space. The company’s flagship brand – Vitality SuperTeas – offers a line of proprietary teas formulated with the goal of revolutionizing conventional organic tea through the infusion of a proprietary blend of artisanal mushrooms with medicinal properties.

Each of Champignon’s Vitality SuperTeas (http://ibn.fm/kzeU6) is carefully formulated with organic ingredients carefully chosen for their ability to provide unique health and performance benefits. The company’s line of SuperTeas include the following: Nourish Force, a blend of reishi ryobus tea mix; Mighty Recharge, created with lion’s mane tropical green ginseng tea mix; and Brain Enhance, a blend of cordycep hibiscus and berry tea mix.

Rich in antioxidants, functional mushrooms are gaining increasing attention for health benefits ranging from strengthening the immune system and providing key vitamins and essential minerals (http://ibn.fm/PnTXR) to boosting overall health, offering skin-enhancing benefits, aiding digestive function and balancing energy levels (http://ibn.fm/xUGqj). Because of their diverse functional properties, functional mushrooms can be used in the production of food products, medicines and even cosmetic products.

A recent market research report by Fortune Business Insights notes that “anticipated growth in consumption of dietary supplements to remain healthy and disease-free is projected to propel the demand for functional mushrooms during the forecast years [2019–2026]. Rapid urbanization, changing lifestyles and increasing per capita income of people is anticipated to aid the growth of the global functional mushrooms market in the upcoming years (http://ibn.fm/qzqUJ).

In addition, the report notes that “increasing product launches by key market players and increasing demand for functional mushroom across the personal care industry to manufacture high-quality products is expected to drive the market growth during the forecast years.”

Another study noted that demand for consumer products infused with the nutritional and bioactive benefits of mushrooms is fueling a global market projected to reach $34.3 billion by 2024, growing at a compound annual growth rate of 8.04% from 2019-2024.

Dedicated to revolutionizing conventional organic teas, coffees and other consumables with the infusion of a proprietary blend of artisanal mushrooms, Champignon is ideally positioned to benefit from this growing market.

The company’s expanding portfolio is crafted with the health-conscious consumer in mind. Headquartered in Vancouver, British Columbia, Champignon’s team aims to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health care and pharmaceutical products.

For more information, visit the company’s website at www.ChampignonBrands.com

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM

• BIGtoken case study reports that Kraft Heinz’s 2019 Walmart holiday promotion achieved 4.5% additional volume, six times return on ad spend
• BIGtoken co-founder says platform has evolved into “full-service marketing stack” that discovers “profound insights” about target audience
• SRAX’s proprietary consumer data management technology put consumers’ data rights at the forefront

SRAX Inc.’s (NASDAQ: SRAX) BIGtoken platform successfully propelled a 2019 holiday season omnichannel campaign at Walmart for leading packaged goods company Kraft Heinz – achieving impressive results and exceeding the client’s goals. SRAX COO Kristoffer Nelson said BIGtoken utilized opt-in panels and offers plus scanned receipts to identify incremental groups of buyers to increase both sales and return on ad spend for Kraft Heinz.

The case study outlining the successful campaign demonstrates how BIGtoken was able to not only identify known customers but also target incremental groups of likely Kraft Heinz buyers (http://ibn.fm/slkFR). The resulting high-value customer insights fueled enhanced audience targeting and messaging – yielding an impressive 4.5% sales lift and a six-to-one return on ad spend (ROAS).

“It’s important for Kraft Heinz to address data accuracy, consumer privacy and emphasize first-party data in this new environment,” said TJ Palladino, Walmart shopper marketing manager for Kraft Heinz. “BIGtoken does all of that. We are thrilled with the results we saw with SRAX’s BIGtoken platform.”

Pre-launch activity by BIGtoken includes numerous data points about the identity habits of consumers. For its promotion, Kraft Heinz used the BIGtoken platform to identity common attributes around consumers who cook meals for key groups during the holiday season.

Kraft Heinz’s successful Walmart promotion featured prominent brands such as Kraft, Velveeta, Oscar-Mayer, Heinz and Stove Top. SRAX’s BIGtoken platform was able to create and identify audiences and design an effective messaging strategy around those brands.

“BIGtoken has evolved from a consumer, opt-in, data platform for advertising activation to a full-service marketing stack,” SRAX COO Kristoffer Nelson stated in a news release (http://ibn.fm/hHX1D). “Beginning with audience insights, marketers can discover profound insights about their target audience to activate against. From here, new insights and learnings are applied inflight to improve performance.”

BIGtoken Brands VP George Stella added, “It’s becoming critical for brands to partner with systems that put emphasis on consumer-first data particles and put consumers’ data rights at the forefront.”

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• American Pregnancy Association endorses Nightfood ice cream as the official recommended ice cream for pregnant women
• APA Endorsement could drive the rapid growth investors are looking for, says NGTF CEO
• Nightfood is significantly more nutritionally appropriate for pregnant women than other ice cream on market

Nightfood Holdings Inc. (OTCQB: NGTF) founder and CEO Sean Folkson recently joined Stuart Smith on SmallCapVoice.com (http://ibn.fm/8Nnnf) to discuss the announcement that NGTF’s better-for-you ice cream is now the recommended ice cream for pregnant women all across the United States, a market of over three million women. This official endorsement comes from the American Pregnancy Association (APA), and it carries significant weight for Nightfood’s market penetration.

In the interview, Folkson discussed the media buzz created by the new endorsement from the APA (http://ibn.fm/iv0gj). The February 20 announcement is a “total game-changer” for the young company, according to Folkson. “This is going to give us the level of demand that’s going to drive the kind of growth that I know our investors – and I guess all investors – are looking for,” he said.

Noting that more than 10,000 new women join the pregnancy demographic every day, Folkson observed that communication and product recommendations within the demographic are exceptionally high and each woman is powerfully committed to making expert-recommended changes to ensure both their health and the health of their babies. That makes the recognition as official ice cream particularly actionable, said Folkson.

“We believe that pregnant women are going to take the guidance from the American Pregnancy Association,” he said. “They’re going to hear about this from their service providers. They’re going to hear about it from each other and from the media that is coming… We expect women to gravitate to Nightfood in massive numbers.”

While Nightfood ice cream wasn’t formulated or designed with pregnant women in mind, it didn’t take the company long to recognize that its commitment to providing a healthier, and more nutritious ice-cream dovetailed perfectly with the nutritional needs of this high-consumption demographic. “With more protein, fiber, calcium, magnesium, and less sugar, fewer calories, as well as ingredients to tackle nighttime heartburn, Nightfood is a more nutritionally appropriate ice cream for pregnant women than anything we’ve ever seen on the market, based on recommendations from the American College of Obstetrics and Gynecology, the Mayo Clinic, and general expert consensus on prenatal nutrition,” said APA President Lynn Handley.

While Nightfood has received several awards and been nationally recognized since it released its first pint of ice cream last year, the APA recommendation is particularly significant as the company looks to broaden distribution. “With pregnant women, we’ve got a consumer base that is out there, and they’re aggressively looking for new products and services to deal with in their new situations,” said Folkson. “We’re going to grow volume and velocity and revenues, which is news, but from a supermarket standpoint, how can you as a category manager decide that you’re not going to carry the official ice cream of the APA? That’s risky business for them, and I think that’s going to present big opportunities for us.”

In addition to supermarkets, Nightfood is looking to expand distribution through what Folkson called “a whole pregnancy media,” including magazines, subscription boxes and other efficient ways to reach the target pregnant audience and introduce them to Nightfood ice cream. “I think it can take on a life of its own where anybody who is going onto a message board or just reading a blog, they’re not going to be able to avoid us,” he said. “They’re going to hear about Nightfood from many different directions.”

Folkson was right. In the last few days, two of the largest pregnancy media outlets have done features of Nightfood ice cream as a result of the endorsement. Both BabyGaga (http://ibn.fm/gXsDc) and TheBump (http://ibn.fm/uxubX) covered the news this week, and Nightfood was also featured on The Rachael Ray Show on Monday, February 24 (http://ibn.fm/dZ794). More major media hits are likely to follow for this brand, which has previously been featured on The Today Show, Oprah Magazine, The Wall Street Journal, Fox Business, USA Today, and many more major outlets.

“The pregnancy piece with this huge customer base gives us the opportunity to get off to a fast start where there’s built-in demand,” Folkson continued. “Anytime we roll into a new supermarket, there will be people there looking for the ice cream. I think that gives us a very strong foundation, and I think from an investor’s standpoint, it probably gives a tremendous amount of stability to the company because we no longer have to wonder about where our foundation revenue and sales volume is going to come from.”

By helping consumers solve their night snacking in a better, healthier and more sleep-friendly way, Nightfood is establishing the leading position in the nighttime-snacking category where American consumers are generally dissatisfied with their options yet are still spending more than $50 billion annually. Nightfood is the creator of delicious, award-winning and better-for-you ice cream formulated by sleep and nutrition experts.

For more information, visit the company’s website at www.Nightfood.com

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF